Beijing, China

Chunyang Jin



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: **Chunyang Jin: Innovator in Monoclonal Antibodies**

Introduction

Chunyang Jin, based in Beijing, China, is a prominent inventor in the field of biotechnology, specializing in the development of monoclonal antibodies. He has been granted a total of three patents, highlighting his innovative contributions to medical science and treatment methodologies.

Latest Patents

Among his significant inventions is a patent for "Antibodies binding human and monkey CD3 and uses thereof." This patent discloses a monoclonal antibody that binds to CD3, a critical component in the immune response, with applications in treating inflammatory diseases. Additionally, it encompasses the development of bispecific antibodies aimed at targeting both CD3 and CD20, providing therapeutic potential for cancer treatment.

Another key invention is the patent for "Bispecific anti-HER2 antibody." This patent describes humanized bispecific antibodies effective against HER2, incorporating variable regions from trastuzumab and pertuzumab. The invention is particularly beneficial for treating various cancers, including breast, gastric, and ovarian cancers, and includes innovative approaches to enhance the therapeutic effectiveness using afucosylated antibodies. It also involves a Chinese Hamster ovary (CHO) mutant cell line that has implications for glycan regulation studies.

Career Highlights

Chunyang Jin currently holds a leading position at Beijing Mabworks Biotech Co. Ltd., where he applies his expertise to advance the development of cutting-edge biopharmaceuticals. His innovative work continues to shape the future of cancer therapies and treatments for inflammatory diseases.

Collaborations

At Mabworks, Chunyang collaborates with eminent professionals in the field, including Feng Li and Sijia Huang. Together, they are driving research forward, contributing significantly to advancements in monoclonal antibody technology and its applications.

Conclusion

Chunyang Jin exemplifies innovation in the biotechnology sector through his impactful patents and collaborative efforts. His work paves the way for novel therapeutic solutions, making significant strides in the treatment of serious medical conditions. As he continues to push the boundaries of this field, Chunyang Jin's contributions are poised to enhance healthcare and improve patient outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…